Defence Therapeutics closes $9.6 million private placement

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) completed a private placement raising $9,595,000 in gross proceeds through the sale of 17,445,455 units at $0.55 per unit.

Each unit comprises one common share and one warrant. The warrants allow holders to purchase additional shares at $0.65 per share within 24 months of issuance.

The biotechnology company closed the financing on March 6, 2026. Two institutional investors participated in $6 million of the placement under a sharing agreement executed the same day. These investors received 10,909,091 warrants exercisable at $0.65 per share for 24 months.

The warrants include an equity blocker provision preventing holders from exercising warrants if doing so would result in ownership exceeding 9.99% of outstanding shares. The institutional investors received 654,546 units as a corporate finance fee and 118,182 units as a non-refundable deposit at the placement price.

Defence Therapeutics plans to use the proceeds to advance its Antibody Drug Conjugate and Radiopharmaceutical programs, develop partnerships, and for working capital purposes. The company paid no finder's fees in connection with the placement.

All securities issued are subject to applicable resale restrictions under Canadian securities laws and exchange policies. The units have not been registered under U.S. securities laws and may not be offered or sold in the United States without registration or applicable exemptions.

The Montreal-based company operates as a biotechnology firm focused on precision intracellular drug delivery using its Accum platform technology.

You May Also Be Interested In

• Filament Health to supply psilocybin drug for veterans PTSD study
• Raymond James sets SpaceX Street-high target, cites defining infrastructure role
• Deutsche Bank Upgrades First Solar (FSLR) to Buy